DUSA Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for Levulan® Photodynamic Therapy for the treatment of esophageal dysplasia.
From: biz.yahoo.com
R) PDT to Treat Esophageal Dysplasia
Posted by Ruslan Abuzant at 5:37 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment